Klump B, Nehls O, Okech T, Hsieh C-J, Gaco V, Gittinger F S, Sarbia M, Borchard F, Greschniok A, Gruenagel H H, Porschen R, Gregor M
Department of Internal Medicine I, University Hospital, Otfried-Müller-Strasse 10, 72076, Tübingen, Germany.
Int J Colorectal Dis. 2004 Jan;19(1):23-42. doi: 10.1007/s00384-003-0499-7. Epub 2003 Jun 21.
In the Dukes' B and C stages of colorectal carcinoma there are considerable variations in the observed courses of the disease. Since post-operative chemotherapy in patients with Dukes' C (node-positive) colon carcinoma has been demonstrated to be effective in improving overall-survival, a more exact prognosis assessment gains additional significance and therapeutic relevance.
One also hopes to derive improved prognostic factors from the clarification of the molecular pathogenesis. Because of its frequency and the accessibility and recognizability of its developmental stages colorectal carcinoma is among the best investigated of all solid tumors. Despite a multitude of suggested molecular candidate markers none of these changes has yet been able enter the everyday life of the clinic. However, it is to be expected that some of the molecular alterations presently discussed will gain importance before long in the clinical treatment of patients with colorectal carcinoma.
Considering also our own findings, this review presents the latest developments in the scientific discussion of the tumor suppressor/oncogenes p53, k-ras, and DCC, biochemical determinants of the 5-fluorouracil metabolism, and defects of the DNA repair system.
在结直肠癌的Dukes' B期和C期,疾病的观察病程存在相当大的差异。由于已证明Dukes' C期(淋巴结阳性)结肠癌患者术后化疗对提高总生存率有效,因此更精确的预后评估具有额外的重要性和治疗相关性。
人们也希望通过阐明分子发病机制得出更好的预后因素。由于结直肠癌的发病率及其发育阶段的可及性和可识别性,它是所有实体瘤中研究最充分的之一。尽管有许多建议的分子候选标志物,但这些变化尚未能进入临床日常应用。然而,可以预期,目前讨论的一些分子改变不久后将在结直肠癌患者的临床治疗中变得重要。
结合我们自己的研究结果,本综述介绍了肿瘤抑制基因/癌基因p53、k-ras和DCC、5-氟尿嘧啶代谢的生化决定因素以及DNA修复系统缺陷的科学讨论的最新进展。